May 1, 1996Experimental Biology and Medicine

Efficacy of the Class III Antiarrhythmic Agent Azimilide in Rodent Models of Ventricular Arrhythmia

View Full Paper

Ask AI

Bookmark

Why the study?

Does azimilide suppress ventricular arrhythmias in rodent models?

Structured PICO

Does azimilide suppress ventricular arrhythmias in rodent models?

Population

Rodent models of ventricular arrhythmia including mouse chloroform model, rat coronary artery ligation and reperfusion (CALR) model, isolated guinea pig hearts, and anesthetized guinea pigs

Intervention

Azimilide administered via i.p. (100 mg/kg), oral (100-300 mg/kg), i.v. (1-30 mg/kg), or in vitro (10 microM)

Comparator

Vehicle control and other class III antiarrhythmic agents (sematilide, dofetilide, E-4031)

Outcome

Suppression of ventricular fibrillation (VF), ventricular tachyarrhythmia (VT), and extrasystoles (VES)surrogate

Azimilide demonstrates a distinct antiarrhythmic profile in rodent models, effectively suppressing ventricular arrhythmias without aggravating cardiac glycoside-induced arrhythmias.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Azimilide's distinct profile in rodent models warrants further preclinical testing; leaves open translation to human ventricular arrhythmia therapy.

Cite This Study

Brooks et al. (1996) studied this question.

synapsesocial.com/papers/6a77a2e1f6b553d308aea145 https://doi.org/10.3181/00379727-212-43995

View Full Paper

Ask AI

Bookmark

Implication

Azimilide's distinct profile in rodent models warrants further preclinical testing; leaves open translation to human ventricular arrhythmia therapy.

Efficacy of the Class III Antiarrhythmic Agent Azimilide in Rodent Models of Ventricular Arrhythmia

Structured PICO

Discussion

Implication

Cite This Study

Efficacy of the Class III Antiarrhythmic Agent Azimilide in Rodent Models of Ventricular Arrhythmia

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider